: iStockAnalyst.com Symbols Feed

Most Active Stock Options December 2, 2009 & Trading Activity

Wed, 02 Dec 2009 21:37:30 GMT

The top ten most active stock option contracts traded today were: Pfizer (PFE) December 18 put OptionsPowerShares QQQ (QQQQ) January 43 Call OptionsPowerShares QQQ December 44 Put OptionsNike (NKE) January 45 Call OptionsPowerShares QQQ December 45 Put OptionsPfizer December 19 put OptionsS&P 500 SPDR (SPY) December 110 Put OptionsS&P 500 SPDR March 110 Put OptionsS&P 500 SPDR June 104 Put OptionsS&P 500 SPDR[More...]

Wall Street Gains As Dollar Declines, Pfizer (NYSE: PFE) Soars

Tue, 01 Dec 2009 22:19:38 GMT

US stocks climbed on Tuesday, sending the Dow Jones industrial average to its highest close for the year, as a weaker dollar boosted commodity prices and shares of raw-material producers.[More...]

Invest In HealthCare!

Tue, 01 Dec 2009 16:52:08 GMT

In 3 of the past 4 market rebounds since 1982, equity gains slowed to a single digit pace in the 2nd year, after the initial rally. Now dividend stocks have extra appeal because they offer a tempting alternative to CDs which pay virtually no interest at all, and long term bonds which pay a little bit more but leave you at the mercy of inflation. Established value companies in stable industries have usually proven a better long-term investment. Before S&P cut Pfizer (PFE) ratings to 'AA' from 'AAA' on Oct 16, 2009, there were 5 companies with AAA credit ratings: Automated Data Processing (ADP), Johnson & Johnson (JNJ), ExxonMobil (XOM) and Microsoft (MSFT). In other words, 2 out of 5 were healthcare companies.[More...]

Pfizer Adds R&D Center In China

Sat, 28 Nov 2009 16:49:48 GMT

Pfizer will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer did not announce the size of capital commitment to the new R&D center.[More...]

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Sat, 28 Nov 2009 15:59:46 GMT

Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular[More...]

Wall Street Ends Higher On Positive Data, Caterpillar (NYSE: CAT) Gains

Wed, 25 Nov 2009 22:19:04 GMT

US stocks finished higher on Wednesday as better-than-expected economic data boosted investor optimism. Trading was relatively thin ahead of Thursday's US Thanksgiving holiday.[More...]

Turnaround Expert: 8 Stocks Below 1999 Highs

Wed, 25 Nov 2009 17:17:49 GMT

"We all know that, despite the big run-up recently, many stocks are still below their highs of a year or two ago," observes turnaround expert George Putnam.[More...]

Wall Street Ends Choppy Session Lower, Boeing (NYSE: BA) Falls

Tue, 24 Nov 2009 22:38:28 GMT

US stocks finished lower on Tuesday after Federal Reserve upped its forecast for economic growth in 2010 but warned that jobless rate would likely remain high next year.[More...]

Twelve Recent Dividend Increasers

Tue, 24 Nov 2009 15:23:29 GMT

Twelve companies last week raised distributions. While this is positive news in comparison to the avalanche of dividend cuts that were occurring just a few months ago, it is important that investors dig deeper into the numbers before they find out the next big thing.[More...]

Markman On The Markets: Is it Time To Buy Monsanto?

Mon, 23 Nov 2009 23:51:11 GMT

Is it time to buy Monsanto Co. (NYSE: MON)? My research tells me that the answer to that question is a definite “yes.”[More...]

NL County home sales stall in October: Uncertainty over jobs at casinos and Pfizer defy statewide trend

Fri, 04 Dec 2009 15:05:00 GMT

Dec. 4--While sales of Connecticut single-family homes sprinted ahead in October, New London County real estate took a breather -- temporarily shaken, analysts said, by employment concerns at three of the region's biggest employers.
Home sales statewide were up 11.5 percent in October compared with last year, but New London County saw a 1 percent decline, according to figures supplied Thursday by The Warren Group, publisher of The Commercial Record.
Les Bray, an agent with William Pitt Sotheby's International Realty in Stonington who provides monthly analysis of local trends, said he had expected numbers to be higher statewide this October, given last year's financial-sector collapse that led to a Wall Street crash and this year's creeping recovery.

: iStockAnalyst.com Symbols Feed

Most Active Stock Options December 2, 2009 & Trading Activity

Wall Street Gains As Dollar Declines, Pfizer (NYSE: PFE) Soars

Invest In HealthCare!

Pfizer Adds R&D Center In China

Cancer Vaccines: Investing Opportunities Beyond Dendreon (NASDAQ: DNDN)

Wall Street Ends Higher On Positive Data, Caterpillar (NYSE: CAT) Gains

Turnaround Expert: 8 Stocks Below 1999 Highs

Wall Street Ends Choppy Session Lower, Boeing (NYSE: BA) Falls

Twelve Recent Dividend Increasers

Markman On The Markets: Is it Time To Buy Monsanto?

NL County home sales stall in October: Uncertainty over jobs at casinos and Pfizer defy statewide trend

OPINION: Eminent Domain: These Grinches Aren't Bringing Christmas Back

Pfizer chief prescribes trust

Business Highlights

EDITORIAL: Eminent domain case haunts New London: Pfizer's departure compounds failure of development on land taken from homeowners.

EDITORIAL: Difficult mix of business, science

Premium baby formula fattens Wyeth Thai sales

Antitrust lawyer files suit to stop Pfizer merger

Boehringer touts expansion

EDITORIAL: Infamous land grab goes for nothing

Mintz Levin Intellectual Property Practice Represents Protalix in $60 Million Licensing Agreement with Pfizer Inc.

Flamel Technologies Announces Third Quarter 2009 Results; Additional New Projects; Cash Increases from $45.1 to $48.8 million

Trading Outlook for BioElectronics Corporation Issued by StockPreacher.com

InSite Vision Reports Third Quarter 2009 Financial Results

Paladin Reports Record Third Quarter 2009 Financial Results

BDNA Webinar Helps Businesses Prepare for and Survive a Software Audit

Celldex Therapeutics Reports Third Quarter and Nine Month 2009 Financial Results

PicksThatMove.Com Announces Investment Opinion on TPS, ML, KOG, GAP and PFE

MichBio Expo &Amp; Conference Exhibitors Profiled

Ligand to Acquire Metabasis for Cash and Contingent Value Rights

Form 4 PFIZER INC For: Nov 30 Filed by: SUSMAN SALLY (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: RINGO WILLIAM R (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: RICCIARDI NATALE S (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: READ IAN C (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: MACKAY MARTIN (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: KINDLER JEFFREY B (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: Lewis-Hall Freda C (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: CANGIALOSI LORETTA V (10K)

Form 4 PFIZER INC For: Nov 30 Filed by: DAMELIO FRANK A (10K)

Form 4 PFIZER INC For: Nov 13 Filed by: SUSMAN SALLY (10K)